As of December 6, 2012, Quantibact A/S’ twisted intercalating nucleic acids (TINA) molecules are available through Eurofins MWG GmbH. See more here.
QuantiBact develops novel generic nucleic acid tools for research and diagnostic use. The objective of the technology is to minimize turnaround time of diagnostic procedures and increase sensitivity and fidelity of quantification. Furthermore the technology enables complex PCR multiplexing as well as utilization of crude sample material. The generic nature of the technology allows application in a broad variety of research and diagnostic applications. QuantiBact was founded on the nucleic acid intercalator research carried out at the University of Southern Denmark, Odense and Hvidovre Hospital, Copenhagen. For more information, visit their website at quantibact.com.
- Press Release: English